Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Spyre: Maintain 'Strong Buy' on additional SPY072 shots on goal Q4 2026 and IBD combination potential.

Spire Global, a satellite data and analytics company, has received positive coverage from an analyst at H.C. Wainwright.

The analyst maintains a 'Strong Buy' rating on the stock, citing the company's growth prospects and potential for a combination with another company.

The analyst also highlights Spire's progress in developing its next-generation satellite constellation.

Spire's stock price has been volatile, reflecting the company's growth prospects and the broader market.